Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Alzheimer's Disease

  Free Subscription


27.03.2017

1 Acta Neuropathol
1 Alzheimers Dement
2 Biochemistry (Mosc)
3 Brain
2 Curr Alzheimer Res
1 Lancet Neurol
1 Nature
10 Neurobiol Aging
1 Neurosci Lett
3 PLoS Med
2 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Neuropathol

  1. SUN M, Bell W, LaClair KD, Ling JP, et al
    Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43.
    Acta Neuropathol. 2017 Mar 22. doi: 10.1007/s00401-017-1701.
    PubMed     Text format     Abstract available


    Alzheimers Dement

  2. KARLAWISH J, Jack CR Jr, Rocca WA, Snyder HM, et al
    Alzheimer's disease: The next frontier-Special Report 2017.
    Alzheimers Dement. 2017 Mar 14. pii: S1552-5260(17)30091.
    PubMed     Text format     Abstract available


    Biochemistry (Mosc)

  3. ANDREEVA TV, Lukiw WJ, Rogaev EI
    Biological Basis for Amyloidogenesis in Alzheimer's Disease.
    Biochemistry (Mosc). 2017;82:122-139.
    PubMed     Text format     Abstract available

  4. RUDNITSKAYA EA, Kolosova NG, Stefanova NA
    Impact of Changes in Neurotrophic Supplementation on Development of Alzheimer's Disease-Like Pathology in Oxys Rats.
    Biochemistry (Mosc). 2017;82:318-329.
    PubMed     Text format     Abstract available


    Brain

  5. BANERJEE G, Kim HJ, Fox Z, Jager HR, et al
    MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
    Brain. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available

  6. REEVES S, McLachlan E, Bertrand J, Antonio FD, et al
    Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Brain. 2017 Feb 4. doi: 10.1093.
    PubMed     Text format     Abstract available

  7. YU M, Engels MM, Hillebrand A, van Straaten EC, et al
    Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study.
    Brain. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format     Abstract available


    Curr Alzheimer Res

  8. RODRIGUEZ-CASADO A, Toledano-Diaz A, Toledano A
    Defective Insulin Signalling, Mediated by Inflammation, Connects Obesity to Alzheimer Disease; Relevant Pharmacological Therapies and Preventive Dietary Interventions.
    Curr Alzheimer Res. 2017 Mar 16. doi: 10.2174/1567205014666170316161848.
    PubMed     Text format     Abstract available

  9. DOMINGUES C, da Cruz E Silva OA, Henriques AG
    Impact of Cytokines and Chemokines on Alzheimer's Disease Neuropathological Hallmarks.
    Curr Alzheimer Res. 2017 Mar 17. doi: 10.2174/1567205014666170317113606.
    PubMed     Text format     Abstract available


    Lancet Neurol

  10. VOSSEL KA, Tartaglia MC, Nygaard HB, Zeman AZ, et al
    Epileptic activity in Alzheimer's disease: causes and clinical relevance.
    Lancet Neurol. 2017;16:311-322.
    PubMed     Text format     Abstract available


    Nature

  11. IACCARINO HF, Singer AC, Martorell AJ, Rudenko A, et al
    Gamma frequency entrainment attenuates amyloid load and modifies microglia.
    Nature. 2016;540:230-235.
    PubMed     Text format     Abstract available


    Neurobiol Aging

  12. FRISONI GB, Jack CR Jr, Winblad B
    Alzheimer's disease biomarker development: a call to funding bodies.
    Neurobiol Aging. 2017;52:117-118.
    PubMed     Text format    

  13. FRISONI GB, Perani D, Bastianello S, Bernardi G, et al
    Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap.
    Neurobiol Aging. 2017;52:119-131.
    PubMed     Text format     Abstract available

  14. PORTERI C, Albanese E, Scerri C, Carrillo MC, et al
    The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues.
    Neurobiol Aging. 2017;52:132-140.
    PubMed     Text format     Abstract available

  15. BOCCARDI M, Gallo V, Yasui Y, Vineis P, et al
    The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology.
    Neurobiol Aging. 2017;52:141-152.
    PubMed     Text format     Abstract available

  16. CERAMI C, Dubois B, Boccardi M, Monsch AU, et al
    Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
    Neurobiol Aging. 2017;52:153-166.
    PubMed     Text format     Abstract available

  17. TEN KATE M, Barkhof F, Boccardi M, Visser PJ, et al
    Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
    Neurobiol Aging. 2017;52:167-182.
    PubMed     Text format     Abstract available

  18. GARIBOTTO V, Herholz K, Boccardi M, Picco A, et al
    Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
    Neurobiol Aging. 2017;52:183-195.
    PubMed     Text format     Abstract available

  19. MATTSSON N, Lonneborg A, Boccardi M, Blennow K, et al
    Clinical validity of cerebrospinal fluid Abeta42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Neurobiol Aging. 2017;52:196-213.
    PubMed     Text format     Abstract available

  20. CHIOTIS K, Saint-Aubert L, Boccardi M, Gietl A, et al
    Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
    Neurobiol Aging. 2017;52:214-227.
    PubMed     Text format     Abstract available

  21. SONNI I, Ratib O, Boccardi M, Picco A, et al
    Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase developme
    Neurobiol Aging. 2017;52:228-242.
    PubMed     Text format     Abstract available


    Neurosci Lett

  22. YAO Z, Yang W, Gao Z, Jia P, et al
    Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease.
    Neurosci Lett. 2017 Mar 18. pii: S0304-3940(17)30246.
    PubMed     Text format     Abstract available


    PLoS Med

  23. SNOWDEN SG, Ebshiana AA, Hye A, An Y, et al
    Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study.
    PLoS Med. 2017;14:e1002266.
    PubMed     Text format     Abstract available

  24. PIERCE AL, Kawas CH
    Dementia in the oldest old: Beyond Alzheimer disease.
    PLoS Med. 2017;14:e1002263.
    PubMed     Text format     Abstract available

  25. DESIKAN RS, Fan CC, Wang Y, Schork AJ, et al
    Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score.
    PLoS Med. 2017;14:e1002258.
    PubMed     Text format     Abstract available


    PLoS One

  26. SON SJ, Kim J, Park H
    Structural and functional connectional fingerprints in mild cognitive impairment and Alzheimer's disease patients.
    PLoS One. 2017;12:e0173426.
    PubMed     Text format     Abstract available

  27. MELLOTT TJ, Huleatt OM, Shade BN, Pender SM, et al
    Correction: Perinatal Choline Supplementation Reduces Amyloidosis and Increases Choline Acetyltransferase Expression in the Hippocampus of the APPswePS1dE9 Alzheimer's Disease Model Mice.
    PLoS One. 2017;12:e0174875.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  28. ZHANG Z, Takeda-Uchimura Y, Foyez T, Ohtake-Niimi S, et al
    Deficiency of a sulfotransferase for sialic acid-modified glycans mitigates Alzheimer's pathology.
    Proc Natl Acad Sci U S A. 2017 Mar 20. pii: 201615036.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: